PT  - JOURNAL ARTICLE
AU  - Charles Brink
AU  - Sven-Erik Dahlén
AU  - Jeffrey Drazen
AU  - Jilly F. Evans
AU  - Douglas W. P. Hay
AU  - Simonetta Nicosia
AU  - Charles N. Serhan
AU  - Takao Shimizu
AU  - Takehiko Yokomizo
TI  - International Union of Pharmacology XXXVII. Nomenclature for Leukotriene and Lipoxin Receptors
AID  - 10.1124/pr.55.1.8
DP  - 2003 Mar 01
TA  - Pharmacological Reviews
PG  - 195--227
VI  - 55
IP  - 1
4099  - http://pharmrev.aspetjournals.org/content/55/1/195.short
4100  - http://pharmrev.aspetjournals.org/content/55/1/195.full
SO  - Pharmacol Rev2003 Mar 01; 55
AB  - The leukotrienes and lipoxins are biologically active metabolites derived from arachidonic acid. Their diverse and potent actions are associated with specific receptors. Recent molecular techniques have established the nucleotide and amino acid sequences and confirmed the evidence that suggested the existence of different G-protein-coupled receptors for these lipid mediators. The nomenclature for these receptors has now been established for the leukotrienes. BLT receptors are activated by leukotriene B4 and related hydroxyacids and this class of receptors can be subdivided into BLT1 and BLT2. The cysteinyl-leukotrienes (LT) activate another group called CysLT receptors, which are referred to as CysLT1 and CysLT2. A provisional nomenclature for the lipoxin receptor has also been proposed. LXA4 and LXB4 activate the ALX receptor and LXB4 may also activate another putative receptor. However this latter receptor has not been cloned. The aim of this review is to provide the molecular evidence as well as the properties and significance of the leukotriene and lipoxin receptors, which has lead to the present nomenclature.